Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-17

Clinical Trial Update: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only [Phase 3]

View source ↗

Summary

Phase 3 trial comparing oral semaglutide to placebo in type 2 diabetes patients managed with diet and exercise shows efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • oral semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2020-02-17